Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Detrusor, Overactive Clear all
Completed Phase 4 Interventional Results available

A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

NCT00224029
View directory record Official record
Conditions
Detrusor Hyperreflexia
Interventions
Oxybutynin transdermal system
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
6
States / cities
Atlanta, Georgia • The Bronx, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2010 · Synced Jul 22, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition

NCT00224016
View directory record Official record
Conditions
Detrusor Hyperreflexia
Interventions
Oxybutynin
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
6 Years to 15 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
23
States / cities
Little Rock, Arkansas • Orange County, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Jul 22, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity

NCT01852058
View directory record Official record
Conditions
Urinary Incontinence
Interventions
OnabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Jul 22, 2026, 5:46 PM EDT
Terminated Not applicable Interventional

Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder

NCT00805779
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
MagPro R30
Device
Lead sponsor
EMKinetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Jul 22, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

NCT01981954
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity, Pediatric
Interventions
Solifenacin succinate
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
6 Months to 4 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 22, 2026, 5:46 PM EDT
Recruiting Not applicable Interventional

Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women

NCT07209397
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant), Mixed Urinary Incontinence, Idiopathic Overactive Bladder With Urinary Incontinence, Idiopathic Overactive Bladder
Interventions
Detrusor nerve radiofrequency ablation, Simulated (sham) detrusor nerve radiofrequency ablation
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
22 Years to 80 Years · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 22, 2026, 5:46 PM EDT
Completed Phase 4 Interventional

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

NCT01661166
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Fesoterodine, Placebo oral tablet
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
30 Years to 90 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Jul 22, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years

NCT00857896
View directory record Official record
Conditions
Overactive Bladder, Neurogenic Detrusor Overactivity
Interventions
Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
8 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Little Rock, Arkansas • Long Beach, California • Overland Park, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Jul 22, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients

NCT01852045
View directory record Official record
Conditions
Urinary Incontinence
Interventions
OnabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Jul 22, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

NCT01192568
View directory record Official record
Conditions
Overactive Detrusor, Neurogenic Bladder
Interventions
Oxybutynin, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 16 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
10
States / cities
Loma Linda, California • Orange, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Jul 22, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Minimizing Pain During Office Intradetrussor Botox Injection

NCT04270526
View directory record Official record
Conditions
Overactive Bladder, Overactive Detrusor, Overactive Bladder Syndrome, Overactivity; Behavior, Urge Incontinence
Interventions
Bicarbonate protocol, Standard protocol
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jul 22, 2026, 5:46 PM EDT
Terminated No phase listed Observational

Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections

NCT03080389
View directory record Official record
Conditions
Overactive Bladder, Overactive Detrusor, Urgency-Frequency Syndrome, UTI
Interventions
Extended Urine Culture
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Jul 22, 2026, 5:46 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Device for Bladder Control for Men With SCI

NCT07668063
View directory record Official record
Conditions
Neurogenic Bladder
Interventions
Noninvasive electrical stimulation device to improve bladder control
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

NCT06059066
View directory record Official record
Conditions
Neurogenic Bladder, Lower Urinary Tract Symptoms, Overactive Bladder, Neuro: Neurogenic Bladder, Neurogenic Detrusor Overactivity
Interventions
Standard number of injection sites, Reduced number of injection sites
Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Jul 22, 2026, 5:46 PM EDT
Recruiting Not applicable Interventional

Yoga for Treatment of Overactive Bladder in Pediatric Patients

NCT05895045
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Overactive Detrusor
Interventions
Yoga
Behavioral
Lead sponsor
Duke University
Other
Eligibility
8 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 22, 2026, 5:46 PM EDT
Recruiting Phase 2Phase 3 Interventional

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

NCT05878951
View directory record Official record
Conditions
Urinary Incontinence, Overactive Bladder Syndrome, Overactive Bladder, Urologic Diseases
Interventions
OnabotulinumtoxinA
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

NCT01565694
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Solifenacin succinate
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
5 Years to 17 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Tarrytown, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Jul 22, 2026, 5:46 PM EDT
Recruiting No phase listed Observational

Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder

NCT05141487
View directory record Official record
Conditions
Urinary Incontinence, Urinary Bladder, Neurogenic
Interventions
UroMonitor, ASCU
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Jul 22, 2026, 5:46 PM EDT
Not yet recruiting Phase 4 Interventional

Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections

NCT06695585
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Frequency, Urge Incontinence, Neurogenic Bladder
Interventions
Lidocaine 2% without vessel constrictor
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jul 22, 2026, 5:46 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity

NCT00495053
View directory record Official record
Conditions
Overactive Bladder
Interventions
hMaxi-K, Placebo
Drug · Other
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Branford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Jul 22, 2026, 5:46 PM EDT